Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials

[1]  Joakim Dillner,et al.  Human papillomavirus and Papanicolaou tests to screen for cervical cancer. , 2007, The New England journal of medicine.

[2]  E. Franco,et al.  The expected impact of HPV vaccination on the accuracy of cervical cancer screening: the need for a paradigm change. , 2009, Archives of medical research.

[3]  Julian Peto,et al.  Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. , 2012, Vaccine.

[4]  J. Cuzick,et al.  Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. , 2012, The Lancet. Oncology.

[5]  J. Cuzick,et al.  Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial. , 2006, Journal of the National Cancer Institute.

[6]  J. Ferlay,et al.  Histological groups for comparative studies , 1998 .

[7]  C. Meijer,et al.  A general primer GP5+/GP6(+)-mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings , 1997, Journal of clinical microbiology.

[8]  Diane Solomon,et al.  Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection. , 2010, Journal of the National Cancer Institute.

[9]  J. Cuzick,et al.  Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. , 2008, Journal of the National Cancer Institute.

[10]  K. Lakshmaiah,et al.  HPV screening for cervical cancer in rural India. , 2009, The New England journal of medicine.

[11]  J. Dillner,et al.  Colposcopic and histopathologic evaluation of women participating in population-based screening for human papillomavirus deoxyribonucleic acid persistence. , 2005, American journal of obstetrics and gynecology.

[12]  J. Berkhof,et al.  Efficacy of HPV-based screening for prevention of invasive cervical cancer : Follow-up of four European randomized controlled trials , 2014 .

[13]  G. Collina,et al.  The reproducibility of CIN diagnoses among different pathologists: data from histology reviews from a multicenter randomized study. , 2009, American journal of clinical pathology.

[14]  J. Peto,et al.  HPV testing in routine cervical screening: cross sectional data from the ARTISTIC trial , 2006, British Journal of Cancer.

[15]  N. Breslow,et al.  Statistical methods in cancer research. Volume II--The design and analysis of cohort studies. , 1987, IARC scientific publications.

[16]  J. Cuzick,et al.  Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomised controlled trial. , 2006, The Lancet. Oncology.

[17]  M. Tonelli,et al.  Recommendations on screening for cervical cancer , 2013, Canadian Medical Association Journal.

[18]  K. Rothman.  Estimation of confidence limits for the cumulative probability of survival in life table analysis. , 1978, Journal of chronic diseases.

[19]  D. Parkin,et al.  Evaluation and monitoring of screening programmes , 2001 .

[20]  Mark Sherman,et al.  The 2001 Bethesda System: terminology for reporting results of cervical cytology. , 2002, JAMA.

[21]  P. Sparén,et al.  Screening-preventable cervical cancer risks: evidence from a nationwide audit in Sweden. , 2008, Journal of the National Cancer Institute.

[22]  J. Cuzick,et al.  Effectiveness of cervical screening with age: population based case-control study of prospectively recorded data , 2009, BMJ : British Medical Journal.

[23]  Henry C Kitchener,et al.  HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. , 2009, The Lancet. Oncology.

[24]  N. Segnan,et al.  European Guidelines for Quality Assurance in Cervical Cancer Screening. Second Edition—Summary Document , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  J. Cuzick,et al.  Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. , 2010, The Lancet. Oncology.

[26]  P. Snijders,et al.  POBASCAM, a population‐based randomized controlled trial for implementation of high‐risk HPV testing in cervical screening: Design, methods and baseline data of 44,102 women , 2004, International journal of cancer.

[27]  S. Thompson,et al.  Quantifying heterogeneity in a meta‐analysis , 2002, Statistics in medicine.

[28]  M. Hakama,et al.  Detection rates of precancerous and cancerous cervical lesions within one screening round of primary human papillomavirus DNA testing: prospective randomised trial in Finland , 2012, BMJ : British Medical Journal.

[29]  J. Berkhof,et al.  Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial , 2007, The Lancet.

[30]  E. Franco,et al.  Primary cervical cancer screening with HPV testing compared with liquid-based cytology: results of round 1 of a randomised controlled trial – the HPV FOCAL Study , 2012, British Journal of Cancer.

[31]  Robert P Fields.  Human papillomavirus DNA versus papanicolaou screening tests for cervical cancer. , 2008, The New England journal of medicine.

[32]  Norman E. Breslow,et al.  The design and analysis of cohort studies , 1987 .

[33]  S Greenland,et al.  Quantitative methods in the review of epidemiologic literature. , 1987, Epidemiologic reviews.